Verition Fund Management
AQST icon

Verition Fund Management’s Aquestive Therapeutics AQST Stock Holding History

Verition Fund Management’s Portfolio AQST Stock Details AQST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-160,197
Closed -$1.03M – 2286
2025
Q4 		$1.03M Buy
+160,197
New +$998K ﹤0.01% 2129
2024
Q4 		– Sell
-199,729
Closed -$995K – 3231
2024
Q3 		$995K Buy
+199,729
New +$777K 0.01% 1894

Other funds holding AQST

BCM
Bratton Capital Management Fort Worth, Texas $40.8M AUM 25.68% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Verition Fund Management's AQST Position: Q1 2026 in Review

Verition Fund Management sold out of Aquestive Therapeutics (AQST) in Q1 2026, closing a stake of 160,197 shares — an estimated $1.03M sold.

Verition Fund Management first reported a position in AQST in Q3 2024 and held it in 2 quarters. The position peaked at $1.03M in Q4 2025. 180 funds tracked by Wall St. Rank hold AQST as of Q1 2026.

  • Verition Fund Management reported no remaining Aquestive Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Verition Fund Management sold 160,197 Aquestive Therapeutics shares in Q1 2026, an estimated $1.03M.
  • Verition Fund Management first reported a position in Aquestive Therapeutics in Q3 2024 and held it in 2 quarters.
  • Verition Fund Management's Aquestive Therapeutics position peaked at $1.03M in Q4 2025.
  • 180 funds tracked by Wall St. Rank held Aquestive Therapeutics as of Q1 2026.

Based on Verition Fund Management's 13F filing for Q1 2026, filed 15 May 2026.